Page last updated: 2024-08-23

valrubicin and thiotepa

valrubicin has been researched along with thiotepa in 4 studies

Research

Studies (4)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (50.00)	29.6817
2010's	2 (50.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ	1
Baselli, EC; Greenberg, RE	1
Hale, K; Lamm, DL; McGee, WR	1
Barlow, LJ; Benson, MC	1

Reviews

3 review(s) available for valrubicin and thiotepa

Article	Year
Intravesical therapy for superficial bladder cancer. Oncology (Williston Park, N.Y.), 2000, Volume: 14, Issue:5 Topics: Adjuvants, Immunologic; Administration, Intravesical; Antibiotics, Antineoplastic; Anticarcinogenic Agents; Antineoplastic Agents; Carcinoma, Transitional Cell; Doxorubicin; Epirubicin; Humans; Interferons; Mitomycin; Mycobacterium bovis; Neoplasm, Residual; Photochemotherapy; Photosensitizing Agents; Thiotepa; Urinary Bladder Neoplasms	2000
Bladder cancer: current optimal intravesical treatment. Urologic nursing, 2005, Volume: 25, Issue:5 Topics: Adjuvants, Immunologic; Administration, Intravesical; Antineoplastic Agents; BCG Vaccine; Cystectomy; Doxorubicin; Drug Administration Schedule; Epirubicin; Humans; Interferon-alpha; Mitomycin; Neoplasm Recurrence, Local; Nurse's Role; Patient Selection; Risk Factors; Salvage Therapy; Survival Rate; Thiotepa; Treatment Failure; United States; Urinary Bladder Neoplasms	2005
Experience with newer intravesical chemotherapy for high-risk non-muscle-invasive bladder cancer. Current urology reports, 2013, Volume: 14, Issue:2 Topics: Administration, Intravesical; Antineoplastic Agents; BCG Vaccine; Carcinoma, Transitional Cell; Deoxycytidine; Docetaxel; Doxorubicin; Gemcitabine; Humans; Mitomycin; Paclitaxel; Taxoids; Thiotepa; Treatment Failure; Urinary Bladder Neoplasms	2013

Other Studies

1 other study(ies) available for valrubicin and thiotepa

Article	Year
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1 Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests	2013

Article

Year

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.

Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1

Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests

2013